- Trial phase
- Approved / Commercialized
- Time to market
- Already commercialized. NeuroStar has been FDA-cleared and marketed since 2008 for adult MDD, with additional indications (OCD, adolescent MDD, anxious depression) added through subsequent 510(k) clearances, most recently in March 2024.
- Why 4/10
- NeuroStar is already FDA-cleared and commercially marketed across multiple indications with no pending PDUFA date, pivotal readout, or Advisory Committee meeting scheduled in the next 12 months. The defining binary events (FDA clearances) have already passed. As a result, impactScore is capped at 4 per the rubric for approved, commercial-stage products with no imminent regulatory binary.
The next catalyst for STIM is the Q4 2026 earnings report, expected in early February 2027, which will show whether the company can sustain its return to operating profitability and positive adjusted EBITDA. The integration of the TrakStar platform with AdvancedMD (scheduled for Q4 2026) and any updates on the Greenbrook clinic expansion and COMP360 collaboration readiness are also worth watching. There is no binary FDA decision or pivotal readout on the horizon since NeuroStar is already fully commercialized.
Price Chart
Executive Summary
NeuroStar Advanced Therapy is a transcranial magnetic stimulation (TMS) system developed by Neuronetics, Inc. (NASDAQ: STIM) for treating major depressive disorder and other psychiatric conditions. It is already FDA-cleared for multiple indications including adult MDD (since 2008), MDD with anxious depression, obsessive-compulsive disorder, and adolescent MDD (ages 15-21, cleared March 2024). The company is a commercial-stage medical technology firm that also operates the Greenbrook network of interventional psychiatry clinics. In Q3 2026, Neuronetics reported $42M in revenue (+12.5% YoY), returned to operating profitability with $541K in operating income, and generated $1.9M in positive adjusted EBITDA. The stock trades around $2.43 with a market cap of roughly $172M, well below the analyst mean price target of $5.75. There are no pending FDA decisions or pivotal trial readouts, making this a commercial execution story rather than a binary catalyst play.
How It Works
NeuroStar uses transcranial magnetic stimulation (TMS), a non-invasive procedure that delivers focused magnetic pulses through a coil placed on the scalp. These pulses stimulate underactive nerve cells in the region of the brain that controls mood. The treatment is drug-free, does not require sedation or anesthesia, and patients remain awake and alert during the session. A typical course involves daily sessions over several weeks.
Trial Status
NeuroStar is already FDA-cleared and commercially available across multiple indications. The company continues to generate real-world evidence through its TrakStar database and presented data at the CTMSS 2026 conference. The Greenbrook clinic network is expanding, and the company has a research collaboration with Compass Pathways to develop delivery models for COMP360 psilocybin treatment if FDA-approved.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 / full-year 2026 earnings report (expected early February 2027) - will show whether operating profitability and positive adjusted EBITDA are sustainable
- TrakStar integration with AdvancedMD practice management platform (scheduled for Q4 2026 availability) - could drive NeuroStar system sales by reducing administrative burden for providers
- Updates on COMP360 psilocybin collaboration with Compass Pathways - Compass reported positive Phase 3 results in February 2026, and FDA approval could create a new growth avenue for Greenbrook clinics
- Greenbrook clinic expansion updates - the National Center of Excellence opened in July 2026 could serve as a blueprint for further clinic growth
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Neuronetics, Inc. 8-K STIM ·Originating report